

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450

APPLICATION NO. FILING DATE		FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/976,618	10/12/2001	Chad A. Mirkin	00-713-i21	1752	
75	590 07/16/2003				
Emily Miao			EXAMINER		
	ehnen Hulbert & Berghoff	RILEY, JEZIA			
32nd Floor 300 S. Wacker	Drive				
Chicago, IL 60606			ART UNIT	PAPER NUMBER	
2			1637	160	
			DATE MAILED: 07/16/2003	19	
				/	

Please find below and/or attached an Office communication concerning this application or proceeding.

4	_							
1 2		Applicati n No.		Applicant(s)				
		09/976,618	976,618 MIRKIN ET AL.					
O	ffice Action Summary	Examiner		Art Unit				
		Jezia Riley		1637				
The MAILING DATE f this communication appears on the cover sheet with the correspondence address Period for Reply								
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status								
_	consive to communication(s) filed on <u>05</u> .	lune 2003 .						
	• • • • • • • • • • • • • • • • • • • •	is action is non-fina	al.					
	<u></u>							
Disposition of								
4)⊠ Claim	(s) <u>243-265,267,291-336,360-406,422,4</u>	26,428,430 and 43	<u>82-444</u> is/are pe	ending in the appl	ication.			
4a) Of the above claim(s) 267,291-336,360-406,426,428 and 432 is/are withdrawn from consideration.								
5) Claim	Claim(s) is/are allowed.							
6)⊠ Claim	6)⊠ Claim(s) <u>243-265,422 and 430</u> is/are rejected.							
7)⊠ Claim	7)⊠ Claim(s) <u>252 and 433-444</u> is/are objected to.							
8)⊠ Claim(s) <u>See Continuation Sheet</u> are subject to restriction and/or election requirement. Application Papers								
9)☐ The sp	pecification is objected to by the Examine	r.						
10) The drawing(s) filed on is/are: a) □ accepted or b) □ objected to by the Examiner.								
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
11)☐ The proposed drawing correction filed on is: a)☐ approved b)☐ disapproved by the Examiner.								
If approved, corrected drawings are required in reply to this Office action.								
12)☐ The oath or declaration is objected to by the Examiner.								
Priority under	35 U.S.C. §§ 119 and 120							
13)☐ Ackno	13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a)∏ All	a) All b) Some * c) None of:							
1.	1. Certified copies of the priority documents have been received.							
2.	2. Certified copies of the priority documents have been received in Application No							
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 								
14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).								
a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.								
Attachment(s)	-	•						
2) Notice of Dra 3) Information D	rierences Cited (PTO-892) Inftsperson's Patent Drawing Review (PTO-948) Disclosure Statement(s) (PTO-1449) Paper No(s) <u>1</u>	5) 🔲 N		(PTO-413) Paper No(atent Application (PT0				
U.S. Patent and Trademark (PTO-326 (Rev. 04-01		tion Summary		Part of Paper No. 14				

Continuation of Disposition of Claims: Claims subject to restriction and/or election requirement are 243-265,267,291-336,360-406,422,426,428,430 and 432-444.

Art Unit: 1637

DETAILED ACTION

- 1. Applicant's election with traverse of group I in Paper No. 13, filed on 6/5/03, is acknowledged. The traversal is on the ground(s) that no adequate reasons and/or examples have been provided to support a conclusion of patentable distinctness between the inventions of groups I-II. This is not found persuasive because the composition of group I can be used in materially different processes such as the invention of Group II, III, or IV. The requirement is still deemed proper and is therefore made FINAL.
- 2. The disclosure is objected to because of the following informalities: The continuation data in the specification are incomplete.

If applicant desires priority under 35 U.S.C. 120 based upon a previously filed application, specific reference to the earlier filed application must be made in the instant application. For benefit claims under 35 U.S.C. 120, 121 or 365(c), the reference must include the relationship (i.e., continuation, divisional, or continuation-in-part) of the applications. This should appear as the first sentence of the specification following the title, preferably as a separate paragraph unless it appears in an application data sheet. The status of nonprovisional parent application(s) (whether patented or abandoned) should also be included. If a parent application has become a patent, the expression "now Patent No. ______" should follow the filing date of the parent application. If a parent application has become abandoned, the expression "now abandoned" should follow the filing date of the parent application.

If the application is a utility or plant application filed under 35 U.S.C. 111(a0 on or after November 29, 2000, the specific reference must be submitted during the pendency of the application and within the later of four months from the actual filing

Page 3

Application/Control Number: 09/976,618

Art Unit: 1637

date of the application or sixteen months from the filing date of the prior application. If the application is a utility or plant application which entered the national stage from an international application filed on or after November 29, 2000, after compliance with 35 U.S.C. 371, the specific reference must be submitted during the pendency of the application and within the later of four months from the date on which the national stage commenced under 35 U.S.C. 371(b) or (f) or sixteen months from the filing date of the prior application. See 37 CFR 1.78(a)(2)(ii) and (a)(5)(ii). This time period is not extendable and a failure to submit the reference required by 35 U.S.C. 119(e) and/or 120, where applicable, within this time period is considered a waiver of any benefit of such prior application(s) under 35 U.S.C. 119(e), 120, 121 and 365(c). A priority claim filed after the required time period may be accepted if it is accompanied by a grantable petition to accept an unintentionally delayed claim for priority under 35 U.S.C. 119(e), 120, 121 and 365(c). The petition must be accompanied by (1) the reference required by 35 U.S.C. 120 or 119(e) and 37 CFR 1.78(a)(2) or (a)(5) to the prior application (unless previously submitted), (2) a surcharge under 37 CFR 1.17(t), and (3) a statement that the entire delay between the date the claim was due under 37 CFR 1.78(a)(2) or (a)(5) and the date the claim was filed was unintentional. The Commissioner may require additional information where there is a question whether the delay was unintentional. The petition should be directed to the Office of Petitions, Box DAC, Assistant Commissioner for Patents, Washington, DC 20231.

Art Unit: 1637

3. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) and the Intellectual Property and High Technology Technical Amendments Act of 2002 do not apply when the reference is a U.S. patent resulting directly or indirectly from an international application filed before November 29, 2000. Therefore, the prior art date of the reference is determined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

Claim Rejections - 35 USC § 103

- 4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was

Art Unit: 1637

not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

5. Claims 243-265, 422, and 430 are rejected under 35 U.S.C. 102(e) as being anticipated by or in the alternative, under 35 U.S.C. 103(a) as obvious over Yguerabide et al. (6,214,560).

Yquerabide et al. discloses a method of light illumination and detection named "DLASLPD" (direct light angled for scattered light only from particle detected) disclose an analyte assay using gold particulate label for specific detection of one or more One or more analytes in a sample can be detected and analytes in a sample. measured by detection and/or measurement of one or more of the specific light scattering properties of metal-like particles. (Summary of the Invention). For example, a certain nucleic acid analyte is composed of about 100 nucleic acid bases and is present in a sample. The sample is prepared so that this nucleic acid is in a single stranded form. Then two or more unique single-stranded "probe" nucleic acid sequences are added to the sample where these different probes bind to different regions of the target Each of these probes has attached to one or more particles (col. 74). strand. Further, the particles can form different types of aggregates that can be detected visually or instrumentally in a microscope or through macroscopic observation or measurements without having to separate free from analyte bound particles. Low particle surface density (less than 0.1 particles per mu²) on a spot and high particle surface density (greater than 0.1 particles per mu²) on a spot are also disclosed which

Art Unit: 1637

are viewed to be inclusive of the instant claims. Useful apparatus and particle types for specific test kits can be constructed. These different test kits, and associated apparatus are useful for applications to consumer use, portable field use, point of care applications such as doctor's offices, clinics, emergency rooms and the like, research laboratories,

such as doctor's offices, clinics, emergency rooms and the like, research laboratories,

and centralized high throughput testing. The above aspects of the provide for detection

of one or more analytes in many different types of samples and diagnostic assay

formats.

In certain analytical and diagnostic assays, it may be preferable to increase the

detectability of the scattered light properties of the particles so that very simplified or no

detection instrumentation is required. By use of the appropriate molecular recognition

binding-pairs and particles it is possible to significantly increase the level of detection

sensitivity. Single-stranded homopolymer sequences, avidin-biotin, streptavidin-biotin,

and other binding-pair systems can be used to "chain-together" and "build-up" many

particles (col 73-76).

The reference describes methods of attachment of substances to particles and other

surfaces. In this method of attaching substances to particles or other surfaces, a two

step approach which involves the use of base material molecules is used. Suitable base

material molecules are any substance which can approach and interact with the surface

by adsorption or other chemical process, and have accessible functional groups to

which additional substances, as for example, binding agents can be attached. As an

Art Unit: 1637

example, the reference has used a derivative of a polyethylene glycol. The properties of this molecule allow for it's use as a base material molecule. Each molecule of this polymer has four amine groups which can serve as linkage sites for the conjugation of additional substances. The hydrophobic backbone of the polyethylene derivative interacts with the particle and is attached to the particle surface by adsorption or some other process. This interaction is very strong. The amine groups do not appear to interact with the particle surface and are accessible as conjugation sites for the attachment of additional substances as for example, binding agents. Using this polymer as the base molecule they have prepared two different types of particle-binding agent reagents. One reagent contains biotin groups as binding agents and the other particlebinding agent reagent was made to contain single-stranded nucleic acids as binding agents. The biotin used for attachment was a chemically modified form where it will covalently link to amine groups. For the nucleic acids, the 5' ends were chemically modified so that they would chemically react with the amine groups. Linker arms of various lengths and composition can also be incorporated into the molecular structure. For example, a small molecular weight base material molecule an be used where it's molecular structure is optimized for attachment to the particle or surface, attachment of most any substance to it with any desired orientation, and with a high level of binding activity. As an example, a linear polypeptide twenty amino acids in length is chemically modified at one terminus by the addition of disulfide or thiol chemical groups. The native polypeptide is composed of amino acids such that the polypeptide chain will not interact with the surface except through the chemically modified end. At the other terminus a

Art Unit: 1637

free amino group exists, or alternatively, has been chemically modified for a desired conjugation process such that most any substance can be attached at this position. This low molecular weight base material molecule then is used in one or more variations of the methods as described herein. (col 77-81). The polyethylene glycol or the polypeptide is viewed to be inclusive of the spacer portion of instant claim 243 for example. And the amine group is viewed to be inclusive of the functional group.

Claims 253-265 have added functions which the prior art has not analyzed such as the diluent oligonucleotide; but given the above 102 rejection analysis substantiating the basic characterization of the composition of the invention being the same as the reference, these added characteristics are presumed to be inherent in the prior art composition. One of ordinary skill in the art will recognize the many different variations of these new attachment methods that can made by varying the chemical groups, molecular weights, molecular structure, labeling reaction conditions, and the type of conjugation chemistry (i.e. cross-linking, covalent attachment, etc.) that is used (col. 81, lines 25-30).

As it is pointed in *In re Fitzgerald* (205 USPQ), page 594, 2nd col., 1st full paragraph, supports the shifting of the burden of proof to the applicant that the instantly claimed invention is novel and unobvious over the prior art. Since both the prior art and the instant application prepare and use composition which appeared to be identical therefore suggesting the instant application under 35 U.S.C. § 103(a).

Page 9

Application/Control Number: 09/976,618

Art Unit: 1637

Double Patenting

6. A rejection based on double patenting of the "same invention" type finds its support in the language of 35 U.S.C. 101 which states that "whoever invents or discovers any new and useful process ... may obtain a patent therefor ..." (Emphasis added). Thus, the term "same invention," in this context, means an invention drawn to identical subject matter. See *Miller v. Eagle Mfg. Co.*, 151 U.S. 186 (1894); *In re Ockert*, 245 F.2d 467, 114 USPQ 330 (CCPA 1957); and *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970).

A statutory type (35 U.S.C. 101) double patenting rejection can be overcome by canceling or amending the conflicting claims so they are no longer coextensive in scope. The filing of a terminal disclaimer <u>cannot</u> overcome a double patenting rejection based upon 35 U.S.C. 101.

7. Claims 243-265 are provisionally rejected under 35 U.S.C. 101 as claiming the same invention as that of claims 243-265 of copending Application No. 09/974,007.

This is a <u>provisional</u> double patenting rejection since the conflicting claims have not in fact been patented.

Claim Objections

- 8. Claims 252 and 430 are objected to because of the following informalities: claim 252 is starting with "the method of claim 251; however, claim 251 is directed to nanoparticles not a method. Claim 430 comprises an ending bracket after "claims 243" in line 2. Appropriate correction is required.
- 9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jezia Riley whose telephone number is 703-305-6855. The examiner can normally be reached on 9:30AM 5:00PM.

Application/Control Number: 09/976,618 Page 10

Art Unit: 1637

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on 703-308-1119. The fax phone numbers for the organization where this application or proceeding is assigned are 703-305-3014 for regular communications and 703-308-4242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

July 15, 2003

PRIMARY EXAMINER